Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
Xiaoyan Wu,1 Lin Wang,1 Yining Qiu,1 Bingyu Zhang,1 Zhenhua Hu,2 Runming Jin1 1Department of Pediatrics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 2Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, China Abstract: T cell acute lymp...
Guardado en:
Autores principales: | Wu X, Wang L, Qiu Y, Zhang B, Hu Z, Jin R |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/306041da56814dcbbe83f900c4bce877 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Profound leukemia cutis in a patient with relapsed T-cell acute lymphoblastic leukemia
por: Ambika Nohria, BA, et al.
Publicado: (2021) -
FEATURES OF IMMUNE CELLS IN ACUTE LYMPHOBLASTIC LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014) -
Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]
por: Wu X, et al.
Publicado: (2018) -
T-Cell Acute Lymphoblastic Leukemia—Current Concepts in Molecular Biology and Management
por: Parveen Shiraz, et al.
Publicado: (2021) -
STAGE-DEPENDENT IMMUNOPATHOGENETIC FEATURES OF ACUTE NONLYMPHOBLASTIC AND ACUTE LYMPHOBLASTIC LEUKEMIA
por: O. V. Smirnova, et al.
Publicado: (2014)